EA200100168A1 - Схема лечения при введении фенилацетилглутамина, фенилацетилизоглутамина и/или фенилацетата - Google Patents
Схема лечения при введении фенилацетилглутамина, фенилацетилизоглутамина и/или фенилацетатаInfo
- Publication number
- EA200100168A1 EA200100168A1 EA200100168A EA200100168A EA200100168A1 EA 200100168 A1 EA200100168 A1 EA 200100168A1 EA 200100168 A EA200100168 A EA 200100168A EA 200100168 A EA200100168 A EA 200100168A EA 200100168 A1 EA200100168 A1 EA 200100168A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- phenyl
- phenylacethyl
- isoglutamine
- glutamine
- administration
- Prior art date
Links
- XBJLFHMAIQTBJX-JTQLQIEISA-N (4s)-5-amino-5-oxo-4-[(2-phenylacetyl)amino]pentanoic acid Chemical compound OC(=O)CC[C@@H](C(=O)N)NC(=O)CC1=CC=CC=C1 XBJLFHMAIQTBJX-JTQLQIEISA-N 0.000 title abstract 3
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 title abstract 2
- 229940049953 phenylacetate Drugs 0.000 title abstract 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 title abstract 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 title 1
- 238000010586 diagram Methods 0.000 title 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 3
- JFLIEFSWGNOPJJ-JTQLQIEISA-N N(2)-phenylacetyl-L-glutamine Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CC1=CC=CC=C1 JFLIEFSWGNOPJJ-JTQLQIEISA-N 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000007864 aqueous solution Substances 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000001802 infusion Methods 0.000 abstract 2
- 230000001613 neoplastic effect Effects 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
В заявке раскрывается способ лечения неопластического заболевания, в том числе рака, включающий введение фармацевтической композиции, фармацевтической композиции, включающей высококонцентрированный водный раствор фенилацетилглутамина и фенилацетилизоглутамина в соотношении 4:1, со скоростью инфузии от 100 до 400 мл/ч. В дополнительном воплощении здесь раскрывается способ лечения неопластического заболевания, в том числе рака, включающий введение фармацевтической композиции, фармацевтической композиции, включающей высококонцентрированный водный раствор фенилацетата и (фенилацетилглутамина или фенилацетилизоглутамина) в соотношении 4:1, со скоростью инфузии от 100 до 400 мл/ч. Здесь также раскрываются фармацевтические композиции, используемые в вышеуказанных способах.Отчет о международном поиске был опубликован 2000.04.27.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/121,567 US6258849B1 (en) | 1998-07-23 | 1998-07-23 | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate |
PCT/US1999/015017 WO2000004894A2 (en) | 1998-07-23 | 1999-07-02 | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200100168A1 true EA200100168A1 (ru) | 2001-08-27 |
EA004179B1 EA004179B1 (ru) | 2004-02-26 |
Family
ID=22397538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200100168A EA004179B1 (ru) | 1998-07-23 | 1999-07-02 | Способ лечения неопластического заболевания при введении фенилацетилглутамина, фенилацетилизоглутамина и/или фенилацетата |
Country Status (21)
Country | Link |
---|---|
US (2) | US6258849B1 (ru) |
EP (1) | EP1098643B1 (ru) |
JP (2) | JP2002521329A (ru) |
KR (4) | KR100399658B1 (ru) |
CN (3) | CN1605334A (ru) |
AT (1) | ATE257378T1 (ru) |
AU (1) | AU759278B2 (ru) |
BR (1) | BR9912356A (ru) |
CA (1) | CA2336945C (ru) |
DE (1) | DE69914084T2 (ru) |
DK (1) | DK1098643T3 (ru) |
EA (1) | EA004179B1 (ru) |
ES (1) | ES2214866T3 (ru) |
HK (1) | HK1037142A1 (ru) |
ID (1) | ID28160A (ru) |
IL (1) | IL140848A (ru) |
NZ (1) | NZ509244A (ru) |
PL (1) | PL213698B1 (ru) |
PT (1) | PT1098643E (ru) |
WO (1) | WO2000004894A2 (ru) |
ZA (1) | ZA200100622B (ru) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6127419A (en) * | 1998-11-23 | 2000-10-03 | Burzynski; Stanislaw R. | Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis |
DE60115465T2 (de) * | 2000-08-29 | 2006-08-03 | Nobex Corp. | Immunoregulierende verbindungen, deren derivate und ihre verwendung |
US8048924B2 (en) | 2001-08-29 | 2011-11-01 | Biocon Limited | Methods and compositions employing 4-aminophenylacetic acid compounds |
US7087219B2 (en) * | 2003-05-28 | 2006-08-08 | Stanislaw R. Burzynski | Toothpaste containing anticancer agents |
US20060246016A1 (en) * | 2003-05-28 | 2006-11-02 | Burzynski Stanislaw R | Toothpaste containing anticancer agents |
US7772108B2 (en) * | 2004-06-25 | 2010-08-10 | Samsung Electronics Co., Ltd. | Interconnection structures for semiconductor devices and methods of forming the same |
DK1773767T3 (en) | 2004-07-07 | 2016-03-21 | Biocon Ltd | Synthesis of azo bound in immune regulatory relations |
CA2575367A1 (en) * | 2004-07-28 | 2006-02-23 | Board Of Regents, The University Of Texas System | 3-halo-2-oxopropionate salts and esters as novel anticancer agents |
EP2319581B1 (en) * | 2004-11-26 | 2015-02-25 | UCL Business PLC | Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy |
US20060205818A1 (en) * | 2005-03-08 | 2006-09-14 | Burzynski Stanislaw R | Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives |
KR20220067001A (ko) | 2009-04-03 | 2022-05-24 | 오세라 테라퓨틱스, 아이엔씨. | L-오르니틴 페닐 아세테이트, 및 이의 제조방법 |
ES2728948T3 (es) | 2009-06-08 | 2019-10-29 | Ucl Business Plc | Tratamiento de la inflamación cerebral usando Fenilacetato de L-Ornitina |
ES2720148T3 (es) | 2010-10-06 | 2019-07-18 | Ocera Therapeutics Inc | Métodos de fabricación de fenilacetato de L-ornitina |
AU2015353703B2 (en) | 2014-11-24 | 2021-04-01 | Ucl Business Plc | Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies |
JP6990170B2 (ja) | 2015-08-18 | 2022-01-12 | オセラ セラピューティクス, インコーポレイテッド | L-オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも1つと組み合わせて用いる筋肉喪失の治療および予防 |
CN108369223B (zh) * | 2015-12-30 | 2021-07-06 | 雀巢产品有限公司 | 用于测定去脂体重的方法 |
US10624869B2 (en) * | 2017-05-08 | 2020-04-21 | Stanislaw R. Burzynski | Methods for the treatment of recurrent glioblastoma (RGBM) |
JP7126520B2 (ja) | 2017-05-11 | 2022-08-26 | オセラ セラピューティクス, インコーポレイテッド | L-オルニチンフェニルアセテートを製造する方法 |
US11344521B2 (en) | 2017-06-12 | 2022-05-31 | Burzynski Research Institute, Inc. | Methods for the treatment of leptomeningeal disease |
CA3067026A1 (en) * | 2017-06-12 | 2018-12-20 | Stanislaw R. Burzynski | Use of antineoplastons to treat leptomeningeal disease |
CN116019798B (zh) * | 2022-07-20 | 2024-03-12 | 中南大学湘雅二医院 | 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4284647A (en) | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
US4470970A (en) | 1981-07-02 | 1984-09-11 | Burzynski Stanislaw R | Purified antineoplaston fractions and methods of treating neoplastic disease |
US5244922A (en) | 1990-09-04 | 1993-09-14 | Burzynski Stanislaw R | Methods for treating viral infections |
US5254587A (en) | 1990-09-04 | 1993-10-19 | Burzynski Stanislaw R | Methods for treating AIDS |
US5605930A (en) | 1991-10-21 | 1997-02-25 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for treating and preventing pathologies including cancer |
CA2254772C (en) | 1996-05-14 | 2004-01-27 | Stanislaw R. Burzynski | Liposomal antineoplaston therapies with markedly improved antineoplastic activity |
-
1998
- 1998-07-23 US US09/121,567 patent/US6258849B1/en not_active Expired - Fee Related
-
1999
- 1999-07-02 NZ NZ509244A patent/NZ509244A/xx not_active IP Right Cessation
- 1999-07-02 IL IL14084899A patent/IL140848A/xx not_active IP Right Cessation
- 1999-07-02 CN CNA2004100032827A patent/CN1605334A/zh active Pending
- 1999-07-02 DE DE69914084T patent/DE69914084T2/de not_active Expired - Lifetime
- 1999-07-02 PL PL345959A patent/PL213698B1/pl unknown
- 1999-07-02 KR KR10-2001-7001021A patent/KR100399658B1/ko not_active IP Right Cessation
- 1999-07-02 AU AU48542/99A patent/AU759278B2/en not_active Ceased
- 1999-07-02 ES ES99932179T patent/ES2214866T3/es not_active Expired - Lifetime
- 1999-07-02 CN CNB2004100616005A patent/CN100400039C/zh not_active Expired - Fee Related
- 1999-07-02 AT AT99932179T patent/ATE257378T1/de active
- 1999-07-02 EP EP99932179A patent/EP1098643B1/en not_active Expired - Lifetime
- 1999-07-02 WO PCT/US1999/015017 patent/WO2000004894A2/en active IP Right Grant
- 1999-07-02 EA EA200100168A patent/EA004179B1/ru not_active IP Right Cessation
- 1999-07-02 CN CNB99811314XA patent/CN1191064C/zh not_active Expired - Fee Related
- 1999-07-02 KR KR10-2003-7002798A patent/KR100414587B1/ko not_active IP Right Cessation
- 1999-07-02 DK DK99932179T patent/DK1098643T3/da active
- 1999-07-02 KR KR10-2003-7002799A patent/KR100417100B1/ko not_active IP Right Cessation
- 1999-07-02 ID IDW20010174A patent/ID28160A/id unknown
- 1999-07-02 JP JP2000560887A patent/JP2002521329A/ja active Pending
- 1999-07-02 KR KR10-2003-7002800A patent/KR100417101B1/ko not_active IP Right Cessation
- 1999-07-02 BR BR9912356-8A patent/BR9912356A/pt not_active Application Discontinuation
- 1999-07-02 CA CA002336945A patent/CA2336945C/en not_active Expired - Fee Related
- 1999-07-02 PT PT99932179T patent/PT1098643E/pt unknown
-
2001
- 2001-01-22 ZA ZA2001/00622A patent/ZA200100622B/en unknown
- 2001-05-22 US US09/863,035 patent/US6943192B2/en not_active Expired - Lifetime
- 2001-11-09 HK HK01107897A patent/HK1037142A1/xx not_active IP Right Cessation
-
2010
- 2010-10-08 JP JP2010228241A patent/JP2011051993A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200100168A1 (ru) | Схема лечения при введении фенилацетилглутамина, фенилацетилизоглутамина и/или фенилацетата | |
EA200000468A1 (ru) | Терапевтическая композиция для введения толтеродина с контролируемым высвобождением | |
DK0913156T3 (da) | Anvendelse af aktiveret protein C til behandling af hyperkoagulationstilstande i forbindelse med sepsis | |
ATE204178T1 (de) | Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin | |
ATE219363T1 (de) | Lösliche prodrugs von paclitaxel | |
RU2003119460A (ru) | Применение пэг-интерферона-а(пэг-inf-а) и рибавирина для лечения хронического гепатита с | |
DE58901002D1 (de) | Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken. | |
SE9301290D0 (sv) | Anvaendning av en somatostatinanalog | |
KR970025615A (ko) | 암 전이 억제제 | |
KR960702313A (ko) | 티아조푸린 및 리바비린을 사용하는 종양질환의 치료방법 (method for the treatment of neoplastic disease utilizing tlazofurin and ribavirin) | |
KR890012942A (ko) | 5-치환된 오르니틴 유도체 | |
ATE499946T1 (de) | Verwendung von hgf für die behandlung von ischämischen erkrankungen der extremitäten | |
EA199901103A1 (ru) | Антивирусный препарат для инъекций | |
KR900017599A (ko) | 종양 치료용 약학 조성물 | |
RU94036169A (ru) | Способ лечения гепатитов | |
RU96122371A (ru) | Способ лечения эндогенных и послеоперационных увеитов | |
RU94041530A (ru) | Способ моделирования у животных внутрисуставного дистрофического процесса | |
JPS5524150A (en) | Anti-malignant-tumor agent | |
RU94025799A (ru) | Способ лечения идиопатического дерматомиозита | |
RU95104039A (ru) | Способ лечения пузырчатки | |
KR920007624A (ko) | 단백질 의약품의 경구투여용 조성물 | |
RU93019884A (ru) | Способ лечения острых гепатитов | |
RU2002104753A (ru) | Способ профилактики и лечения лейкоза крупного рогатого скота | |
RU94011850A (ru) | Применение диакватрихлоркупират метилметионинсульфония в качестве стимулятора биосинтетической функции печени | |
RU93045474A (ru) | Способ лечения острого и хронического простатита |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |
|
NF4A | Restoration of lapsed right to a eurasian patent |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |